Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

Core Insights - Regeneron Pharmaceuticals has announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies, which will nearly double its U.S. large-scale manufacturing capacity [1][3] - The total investment in this expansion is estimated to exceed $3 billion, contributing to Regeneron's ongoing and planned investments in New York and North Carolina, expected to total more than$7 billion [1][2] - The expansion will create high-paying jobs and support economic growth in the regions involved, with a focus on advancing biotech innovation [2][3] Investment and Job Creation - Regeneron is investing approximately $3.6 billion in expanding its Tarrytown campus in New York, which will create 1,000 full-time, high-skill jobs [2] - The company is also constructing a new fill/finish manufacturing facility in Rensselaer, New York, and has acquired over 1 million square feet of property in Saratoga Springs for production support and potential additional manufacturing capacity [2][3] Partnership with FUJIFILM - The partnership with FUJIFILM is aimed at ensuring continuity of supply for Regeneron's biologic medicines, with technology transfer beginning immediately and a ten-year term for the agreement [1][3] - Both companies express confidence in the collaboration, emphasizing their shared vision to make transformative medicine accessible to patients [3] Workforce Growth - Over the past five years, Regeneron has added more than 7,000 jobs, primarily in high-paying R&D and manufacturing roles based in the United States [3]